NASDAQ$ZBIO
Zenas Biopharma Inc · Q3 2025 earnings
Q3 2025 earnings ·
Briefing
ZBIO reported Q3 2025 a net loss of $38.0M.
For Q3 2025, ZBIO reported net loss was $38.0M. The filing discusses operating performance, liquidity, and outlook in MD&A.
- Net loss $38.0M.
- MD&A covers R&D, cash runway, and sector-specific risks.
- MD&A covers R&D, cash runway, and sector-specific risks.
Headline financials
Revenue & EPS history
Zenas Biopharma Inc · Revenue · Quarterly
$0
Forward guidance
Outlook focuses on cash runway, pipeline milestones, and cost discipline as the company works toward profitability.
Tailwinds
- Cash and equivalents support operations into upcoming milestones.
- Clinical or product pipeline progress noted in MD&A.
Headwinds
- Ongoing operating losses and R&D spend pressure near-term earnings.
- Financing, dilution, or partnership timing may affect liquidity.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 4 quarterly earnings reports · overlaid with Q3 2025
+4.3%
Avg return
Earnings day
+3.2%
Avg return
5 days after
+3.2%
Avg return
30 days after
80%
4 / 5 earnings
Positive
+12.2%
Q1 2025
Best reaction
-3.1%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.9% | -11.7% | +3.0% | |
| Q3 2025 | +1.7% | +1.9% | +15.3% | |
| Q2 2025 | +6.7% | +12.8% | +35.3% | |
| Q1 2025 | +12.2% | +32.3% | +19.0% | |
| Q3 2024 | -3.1% | -19.6% | -56.5% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro